Every round on record, with the sources behind each and the investors on them.
A clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases
breye.comCopenhagen, DenmarkBiotech
11 sources · checked 5 times, last 4d ago
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
BioInnovation Institute (BII), the Danish Growth Foundation (Vækstfonden), and the Danish Innovation Foundation (Innovationsfonden) are identified as providing pre-seed support, not as investors in this seed round.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $75.8M €67.5 million | 2026-09-29 | Mission BioCapital, Novo Holdings | No recent discussion |
11 sources · checked 5 times, last 4d ago [ VERIFIED · CORRECTED ] read against 4 of 11 sources
| ||||
Breye Therapeutics develops orally administered small-molecule ophthalmology drugs for patients at risk of vision loss from retinal diseases.
Breye is addressing retinal diseases in which current late-stage treatments are invasive intravitreal injections and early or moderate non-proliferative diabetic retinopathy has few treatment options. Its €67.5 million Series A is intended to move the oral lead asset danegaptide into a randomized Phase 2 proof-of-concept trial after Phase 1b showed good tolerability and early imaging signals consistent with reduced vascular leakage.
Checked against 13 sources on Sep 29
| Seed [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $4.0M €4 million | 2022-11-10 | Novo Holdings, Sound Bioventures | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources BioInnovation Institute (BII), the Danish Growth Foundation (Vækstfonden), and the Danish Innovation Foundation (Innovationsfonden) are identified as providing pre-seed support, not as investors in this seed round. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: breye.com, labiotech.eu·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 2 sources·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: BioInnovation Institute, Danish Innovation Foundation (Innovationsfonden), Danish Growth Foundation (Vækstfonden)